Compare Indonesia Energy Corporation Limited (INDO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Recursion Pharmaceuticals Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.71 (market cap $42.62M), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 54.2× Indonesia Energy Corporation Limited's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| INDO | RXRX | |
|---|---|---|
Market Cap | $42.62M | $2.31B |
Volume | 60,371 | 40,478,768 |
Sector | Energy | Health |
52-Week High | $6.74 | $6.79 |
52-Week Low | $2.49 | $2.84 |
Typical Hold Time | 24 Days | 22 Days |
Enterprise Value | $37.56M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $5.10 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from analysts, fundamental weaknesses and negative earnings trends pose significant risks. The stock's outlook depends on successful execution of drilling operations to improve financial performance. Investors should weigh high operational risks against potential growth from new production.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
